Comparison Between the Efficacy of Albumin Versus Hyaluronic Acid Scaffold in Combination With Concentrated Growth Factors as an Adjunct to Non-surgical Treatment of Periodontitis

NCT ID: NCT07081230

Last Updated: 2025-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-07

Study Completion Date

2025-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective is to clinically evaluate the efficacy of albumin versus hyaluronic acid scaffolds in combination with concentrated growth factors in the non- surgical treatment of stage II/III periodontitis.

The secondary objective is to evaluate the duration and concentration of different growth factors release in the gingival crevicular fluid.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

III. Treatment Procedures:

Three weeks prior to treatment all patients will receive phase I periodontal therapy in the form of non-surgical mechanical debridement using ultrasonic and hand instruments, oral hygiene instructions will be demonstrated to all patients.

Group I (Test group 1): will receive mechanical debridement and injection of hyaluronic acid mixed with growth factor concentrates in the periodontal pocket, the growth factor concentrates will be prepared by collecting peripheral blood using 9-10 mL tubes without adding any additives, following blood collection, the blood tubes will be placed in a centrifuge for the 8-min ,two to four milliliters of the initial portion of plasma PPP (platelet-poor plasma) is then collected with a syringe and discarded, leaving the other blood portions, the LPCGF (liquid phase concentrated growth factors) from buffy coat is collected then it will be mixed using a female-female connector with hyaluronic acid and injected into the pocket.

Group II (Test group 2) : will receive mechanical debridement and ALB-PRF will be prepared by collecting peripheral blood using 9-10 mL tubes without adding any additives, following blood collection, the blood tubes will be placed in a centrifuge for the 8-min ,Two to four milliliters of the initial portion of plasma (platelet-poor plasma) is then collected with a syringe and placed into a heating device , while the other blood portions (buffy coat, LPCGF, and red blood cells) are placed in a cooling storage bag. The syringes containing PPP are then inserted into a heating device for human serum albumin denaturation plasma to produce the albumin gel. After 10 minutes at an operating temperature of 75°C, the syringes are then removed and allowed to cool in a cooling storage bag and protected from ambient light. The LPCGF (liquid phase concentrated growth factors) from buffy coat are then collected. Thereafter, the albumin gel and the liquid-CGF are mixed between syringes by passing back and forth (roughly 10×) using a female-female connector to create ALB-PRF which is ready to be injected in the periodontal pocket, ALB-PRF gel will be injected into periodontal pocket by special needle until it is full.

Group III (Control group): will receive mechanical debridement only. All patients will be advised not to eat hard food, they were also advised not to brush the area for 12h or to floss or use interproximal cleaning devices for ten days. During the study period, the patients were instructed to continue regular tooth brushing and interdental cleansing, also instructed not to use any mouth washes for the Duration of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Patients will be randomly divided into 3 groups with (10) patients each. Group I (Test group 1): patients will receive hyaluronic acid mixed with concentrated growth factors after mechanical debridement.

Group II (Test group 2): patients will receive Albumin gel mixed with concentrated growth factors after mechanical debridement.

Group III (Control group): patients will receive mechanical debridement only.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Randomization will be performed before starting the study by computer generated tables to allocate each patient in his group.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HYALURONIC ACID MIX WITH CGF

patients will receive hyaluronic acid mixed with concentrated growth factors after mechanical debridement

Group Type EXPERIMENTAL

SRP with hyaluronic acid

Intervention Type COMBINATION_PRODUCT

patients will receive hyaluronic acid mixed with concentrated growth factors injected into the periodontal pocket after mechanical debridement

ALB PRF

patients will receive Albumin gel mixed with concentrated growth factors after mechanical debridement

Group Type EXPERIMENTAL

SRP + Injectable Platelet-Rich Fibrin

Intervention Type COMBINATION_PRODUCT

patients will receive Albumin gel mixed with concentrated growth factors injected into the periodontal pocket after mechanical debridement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SRP with hyaluronic acid

patients will receive hyaluronic acid mixed with concentrated growth factors injected into the periodontal pocket after mechanical debridement

Intervention Type COMBINATION_PRODUCT

SRP + Injectable Platelet-Rich Fibrin

patients will receive Albumin gel mixed with concentrated growth factors injected into the periodontal pocket after mechanical debridement

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aging from 25-45 years
* Patients with stage II /III periodontitis

Exclusion Criteria

* Any systemic condition that may impact the study (21)
* Poor oral hygiene
* Pregnant and breastfeeding women
* Smoking patients.
* Patients received periodontal treatment in the last 6 months
* Unable to comply with study protocol
Minimum Eligible Age

25 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

husain abduljalil alam

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

husain abduljalil alam

Principal Investigator,BDS, Oral Medicine, Periodontology, Diagnosis, and Oral Radiology Department,

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mansoura university Faculty of dentistry

Al Mansurah, Mansoura, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

HUSAIN A.JALIL ALAM, BDS

Role: CONTACT

+201500838200

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

husain a.jalil alam, BDS

Role: primary

+201500838200

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A03010250M

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.